Synthesis and Characterization of the Chitosan-Coated Methotrexate-Conjugated Hybrid Magnetic Nanoparticles

Year 2026, Volume: 5 Issue: 1, 18 - 24, 05.02.2026

Ebru Kuyumcu Savan , Süleyman Köytepe , İmren Özcan , Burhan Ateş , Sevgi Balcıoğlu

https://doi.org/10.71133/anatphar.1822948

https://izlik.org/JA32JR44RF

Abstract

In this study, a rapid and alternative magnetic nanoparticle structure was developed for the hyperthermia treatment of cancer, a growing and significant problem. Magnetic nanoparticles hold significant potential in cancer treatment. The most important feature of magnetic nanoparticles is their ability to be targeted to tumor sites by applying an external magnetic field. Furthermore, their small size, high surface area, and the ease of control of their surface structure through surface modification are other important properties. The ability of magnetic nanoparticles to acquire drug-carrying capacity through surface modification provides a significant application advantage. Another feature is that the magnetic field applied to the cancerous area induces hyperthermia, thereby destroying cancer cells. Therefore, the prepared magnetic-core nano cancer drugs exhibit a dual-agent therapeutic effect. In this study, we first synthesized nanosized, magnetically steerable CoFe2O4 nanoparticles. Subsequently, these nanoparticles were surface-modified, and the anti-carcinogenic chemotherapeutic drug methorotaxane was conjugated. In the final phase of the study, chitosan was coated on the surface of the methotrexate-conjugated magnetic nanoparticle to increase biocompatibility. All structures obtained were initially characterized using FTIR and EDX spectroscopy. Furthermore, all CoFe2O4-based structures were morphologically characterized using scanning electron microscopy. This resulted in the creation of a dual-action drug structure that offers both diagnostic, monitoring, and therapeutic potential.

Keywords

Magnetic Nanoparticle , Surface Modification , Hybrid Magnetic Nanoparticles

Ethical Statement

The authors declare that no human or animal studies have been conducted in this article.

References

• [1] Hergt R, Dutz S, Muller R, Zeisberger M. Magnetic particle hyperthermia: nanoparticle magnetism and materials development for cancer therapy. J Phys: Condens Mat 2006;18:S2919–S2934.
• [2] Jordan A, Scholz R, Wust P, Fahling H, Felix R. Magnetic fluid hyperthermia (MFH): cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater 1999;201:413–419.
• [3] Mornet S, Vasseur S, Grasset F, Duguet E. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem 2004;14:2161–2175.
• [4] Rosensweig RE. Ferrohydrodynamics. 1997, New York: Dover Publications, Inc.
• [5] Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater 2002;252:370–374.
• [6] Hergt R, Dutz S. Magnetic particle hyperthermia—biophysical limitations of a visionary tumour therapy. J Magn Magn Mater 2007;311:187–192.
• [7] Moroz P, Jones S, Gray B. Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 2002;18:267–284.
• [8] A. Jordan A Wust P, Fa¨hling H, John W, Hinz A, Feliz R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 2009;25:499–511.
• [9] DeNardo SJ, DeNardo GL, Miers LA, Natarajan A, Foreman AR, Gruettner C, Adamson GN, Ivkov R. Development of Tumor Targeting Bioprobes (111In- Chimericn L6 Monoclonal Antibody Nanoparticles) for Alternating Magnetic Field Cancer Therapy. Clin Cancer Res 2005;11:7087s.
• [10 Brezovich I. Low frequency hyperthermia:capactive and ferromagnetic thermoseed methods. Med Phys 1988;16:82–111.
• [11] Seo WS, Lee JH, Sun X, Suzuki Y, Mann D, Liu Z, Terashima M, Yang PC, McConnell MV, Nishimura DG, Dai H. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat Mater 2006;5:971–976.
• [12] Shliomis M. Effective viscosity of magnetic suspensions. Sov Phys Usp 1973;17:153–169.
• [13] Gellermann J, Wlodarczyk W, Hildebrandt B, Ganter H, Nicolau A, Rau B, Tilly W, Fähling H, Nadobny J, Felix R, Wust P. Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system. Cancer Res 2005;65:5872–5880.
• [14] Zhao DL, Lv Q, Shen ZM. Fabrication and microwave absorbing properties of Ni–Zn spinel ferrites. J Alloys Compd 2009;480: 634-638.
• [15] F. Gao, Z. Yan, J. Zhou, Y. Cai, J. Tang, Methotrexate-conjugated magnetic nanoparticles for thermochemotherapy and magnetic resonance imaging of tumor. J Nanopart Res 2012;14: 1160-1170.
• [16] Sugimoto M. The Past, Present, and Future of Ferrites. J Am Ceram Soc 1999;82:269-280.
• [17] Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-Immobilized Poly(ethylene glycol) Magnetic Nanoparticles for MR Imaging and Drug Delivery. Small 2006;2:785–792.
• [18] Akhtar MF, Afzaal A, Saleem A, Roheel A, Khan MI, Imran M. A comprehensive review on the applications of ferrite nanoparticles in the diagnosis and treatment of breast cancer. Med Oncol 2024;41:53.
• [19] Yin Y, Lu Y, Lin S, Wang L, Wang Z, Dong X, Cao J, Wu L, Shen S. BSA-Coated Copper Ferrite Nanoparticles Loaded with Doxorubicin for Synergistic Ferroptosis-Chemotherapy for Cancer Treatment. ACS Appl Bio Mater 2025;8(8): 7322-7330.
• [20] Nowak-Jary J, Płóciennik A, Machnicka B. Functionalized Magnetic Fe3O4 Nanoparticles for Targeted Methotrexate Delivery in Ovarian Cancer Therapy. Int J Mol Sci 2024;25(16):9098.